SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors
Various studies have shown that SARS-CoV-2 is a highly immunogenic virus. It is known that different types of immunogenic viral pathogens could trigger the formation of HLA antibodies. Therefore, there is a concern that the SARS-CoV-2 could also induce the development of HLA antibodies in volunteers...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2022-04-01
|
| Series: | Intervirology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/524016 |
| _version_ | 1828366225464360960 |
|---|---|
| author | Ashraf Dada Khalid Elhassan Rayan Mohammed Bawayan Ghadeer Albishi Lama Hefni Sawsan Bassi Turki Sobahy Edward Cupler Nabeela AlBaz Ghassan Wali Basem Alraddadi Abeer N. Alshukairi |
| author_facet | Ashraf Dada Khalid Elhassan Rayan Mohammed Bawayan Ghadeer Albishi Lama Hefni Sawsan Bassi Turki Sobahy Edward Cupler Nabeela AlBaz Ghassan Wali Basem Alraddadi Abeer N. Alshukairi |
| author_sort | Ashraf Dada |
| collection | DOAJ |
| description | Various studies have shown that SARS-CoV-2 is a highly immunogenic virus. It is known that different types of immunogenic viral pathogens could trigger the formation of HLA antibodies. Therefore, there is a concern that the SARS-CoV-2 could also induce the development of HLA antibodies in volunteers, who donate convalescent plasma after their recovery from COVID-19. HLA antibodies have been identified as the main cause for transfusion-related acute lung injury (TRALI), a well-documented life-threatening complication of transfusions. The TRALI risk could be high in COVID-19 patients who need convalescent plasma, as such patients usually have already an impaired respiratory system affected by the SARS-CoV-2 infection. In this study, we screened 34 convalescent plasma donors on the presence of antibodies against HLA class I and II antigens. All included donors have no any history of sensitization events such as blood transfusions, pregnancy, or previous transplants. We found a high rate of HLA antibody formation in convalescent plasma donors. The frequency of positivity for HLA antibodies for class I, class II, class I and II, and the overall reactivity was 23%, 31%, 46%, and 76%, respectively. The presented data suggest a closed correlation between SARS-CoV-2 virus infection and the development of HLA antibodies in recovered convalescent plasma donors. This finding might have the potential to reduce the risk of TRALI and mortality rate in COVID-19 patients by implementing HLA diagnostic strategies before the administration of convalescent plasma. |
| first_indexed | 2024-04-14T05:42:22Z |
| format | Article |
| id | doaj.art-a9e8d955e3fb44bc991d29d038752759 |
| institution | Directory Open Access Journal |
| issn | 0300-5526 1423-0100 |
| language | English |
| last_indexed | 2024-04-14T05:42:22Z |
| publishDate | 2022-04-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Intervirology |
| spelling | doaj.art-a9e8d955e3fb44bc991d29d0387527592022-12-22T02:09:25ZengKarger PublishersIntervirology0300-55261423-01002022-04-011610.1159/000524016524016SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma DonorsAshraf Dada0https://orcid.org/0000-0002-9893-7496Khalid Elhassan1Rayan Mohammed Bawayan2Ghadeer Albishi3Lama Hefni4Sawsan Bassi5Turki Sobahy6Edward Cupler7https://orcid.org/0000-0003-0958-8931Nabeela AlBaz8Ghassan Wali9Basem Alraddadi10Abeer N. Alshukairi11https://orcid.org/0000-0002-9565-3527Department of Pathology and Laboratory Medicine/King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaDepartment of Pathology and Laboratory Medicine/King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaDepartment of Pathology and Laboratory Medicine/King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaDepartment of Pathology and Laboratory Medicine/King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaResearch Center of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaResearch Center of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaResearch Center of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaResearch Center of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaDepartment of Pathology and Laboratory Medicine/King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaSection Infection Diseases, Department of Internal Medicine of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaSection Infection Diseases, Department of Internal Medicine of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaSection Infection Diseases, Department of Internal Medicine of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaVarious studies have shown that SARS-CoV-2 is a highly immunogenic virus. It is known that different types of immunogenic viral pathogens could trigger the formation of HLA antibodies. Therefore, there is a concern that the SARS-CoV-2 could also induce the development of HLA antibodies in volunteers, who donate convalescent plasma after their recovery from COVID-19. HLA antibodies have been identified as the main cause for transfusion-related acute lung injury (TRALI), a well-documented life-threatening complication of transfusions. The TRALI risk could be high in COVID-19 patients who need convalescent plasma, as such patients usually have already an impaired respiratory system affected by the SARS-CoV-2 infection. In this study, we screened 34 convalescent plasma donors on the presence of antibodies against HLA class I and II antigens. All included donors have no any history of sensitization events such as blood transfusions, pregnancy, or previous transplants. We found a high rate of HLA antibody formation in convalescent plasma donors. The frequency of positivity for HLA antibodies for class I, class II, class I and II, and the overall reactivity was 23%, 31%, 46%, and 76%, respectively. The presented data suggest a closed correlation between SARS-CoV-2 virus infection and the development of HLA antibodies in recovered convalescent plasma donors. This finding might have the potential to reduce the risk of TRALI and mortality rate in COVID-19 patients by implementing HLA diagnostic strategies before the administration of convalescent plasma.https://www.karger.com/Article/FullText/524016sars-cov-2covid-19hla antibodiesimmune responseconvalescent plasma |
| spellingShingle | Ashraf Dada Khalid Elhassan Rayan Mohammed Bawayan Ghadeer Albishi Lama Hefni Sawsan Bassi Turki Sobahy Edward Cupler Nabeela AlBaz Ghassan Wali Basem Alraddadi Abeer N. Alshukairi SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors Intervirology sars-cov-2 covid-19 hla antibodies immune response convalescent plasma |
| title | SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors |
| title_full | SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors |
| title_fullStr | SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors |
| title_full_unstemmed | SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors |
| title_short | SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors |
| title_sort | sars cov 2 triggers the development of class i and class ii hla antibodies in recovered convalescent plasma donors |
| topic | sars-cov-2 covid-19 hla antibodies immune response convalescent plasma |
| url | https://www.karger.com/Article/FullText/524016 |
| work_keys_str_mv | AT ashrafdada sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT khalidelhassan sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT rayanmohammedbawayan sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT ghadeeralbishi sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT lamahefni sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT sawsanbassi sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT turkisobahy sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT edwardcupler sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT nabeelaalbaz sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT ghassanwali sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT basemalraddadi sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors AT abeernalshukairi sarscov2triggersthedevelopmentofclassiandclassiihlaantibodiesinrecoveredconvalescentplasmadonors |